Vaxxas

Vaxxas

Commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
$92—138m (Dealroom.co estimates Dec 2022.)
Brisbane Queensland (HQ), Sydney New South Wales (founding location)
  • Edit
DateInvestorsAmountRound
-

N/A

-

$15.0m

Series A

$25.0m

Series B

AUD50.0k

Grant

AUD50.0k

Grant

$5.0m

Grant
*

$22.0m

Grant
*

$23.0m

Late VC
*

$4.3m

Grant
*

AUD4.0m

Grant
Total Funding$97.0m

Recent News about Vaxxas

Edit
More about Vaxxasinfo icon
Edit

Vaxxas is a pioneering company in the biotechnology sector, focused on revolutionizing the way vaccines are delivered. The company has developed a novel, needle-free vaccination technology that significantly improves the efficacy and performance of both existing and next-generation vaccines. Vaxxas primarily serves healthcare providers, pharmaceutical companies, and global health organizations. Operating in the global healthcare market, Vaxxas employs a business model that includes partnerships, licensing agreements, and direct sales to generate revenue. By collaborating with renowned organizations, Vaxxas maximizes the impact of its technology on a global scale. The company's innovative approach aims to create a healthier world by making vaccinations more effective and accessible.

Keywords: biotechnology, needle-free, vaccines, healthcare, efficacy, innovation, partnerships, licensing, global health, technology.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.